Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from August 25, 2025

Partial Published before the outcome was known, scored automatically when the window closed on November 23, 2025.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted
$57.76 Published $64.69 Target $47.63 Window close $62.32 Peak
$56.50 – $58.00Entry zone — fair-value band
$57.76Published — price the day we called it
$64.69Target — the price the thesis aimed for
$62.32Peak — highest point inside the window, not a realized return
$47.63Window close — end-of-window price, context only

What happened

Partial

Reached 66% of the predicted growth at its peak, without hitting the target.

Peak price
$62.32
peak on September 19, 2025 — not a realized return
Peak gain
+7.9%
peak, from the publication price
Window close
$47.63
end-of-window price, context only
Days to target
—
Window
August 25, 2025 – November 23, 2025

The thesis — published August 25, 2025

Predicted growth
+12%
over the measurement window
Target price
$64.69
the price the thesis aimed for
Entry zone
$56.50 – $58.00
the fair-value band we waited for
Price at publication
$57.76
published August 25, 2025
Confidence
60%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Short-term news risk is high. Recent strength is now facing a lawsuit, a negative call from Zacks, and new rivals in India for its key diabetes and weight-loss drugs. If buying, favor small buys on down days with strict limits and patience. We are watching for clearer updates on the legal case and competition before building a larger position over the next three months, and price could swing more than usual until things settle.

Primary drivers

  • Strong diabetes and obesity drugs, but distracting headlines for now
  • Lawsuit and a negative analyst label are pressuring investor mood
  • If buying, do it on pullbacks with small size and strict limits
  • Wait to see how new rivals, especially in India, affect sales

How it played out

NVO: thesis only partly played out

Lyra published NVO at 57.76 on 2025-08-25, with 12% expected growth over a short-term window. The thesis pointed to strong diabetes and obesity drugs, but also high news risk, a lawsuit, a negative analyst label, and new rivals in India. It favored small buys on down days and patience until clearer updates arrived.

Inside the window, NVO rose to 62.32 on 2025-09-19, a 7.9% peak gain. It stayed below the 64.69 target. By 2025-11-23, it ended at 47.63. The thesis partly played out because there was an early rise, but the target was never reached and the signal finished lower.

What happened during the window

On 2025-11-05, Novo Nordisk reported third-quarter sales growth of 5% to 75 billion Danish kroner and lowered its full-year growth outlook. The same report said the company was in a bidding fight with Pfizer for Metsera.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals